Reuters ahead on Genzyme talking to other parties, earnings forecast

Amid a flood of news during Genzymes investor day on Oct 22, Reuters was alone in alerting the biotech companys comment that it was in the early stages of talking to other companies. The headline immediately sent shares of Genzyme, the subject of a hostile takeover bid by Sanofi, up 1.3 percent and was unmatched by rivals. Reuters also was ahead in alerting Genzymes key earnings forecast for 2011, beating Dow Jones and Bloomberg. The forecast was significant because, according to Genzyme, it justified a price as high as $89 per share, based on the multiple underlying Sanofis $69 per share offer.